Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jul 27;9(8):e18742.
doi: 10.1016/j.heliyon.2023.e18742. eCollection 2023 Aug.

Antibacterial mechanism of action and in silico molecular docking studies of Cupressus funebris essential oil against drug resistant bacterial strains

Affiliations

Antibacterial mechanism of action and in silico molecular docking studies of Cupressus funebris essential oil against drug resistant bacterial strains

Caixin Yuan et al. Heliyon. .

Abstract

The primary objective of this research work was to study the antibacterial effects of Cupressus funebris essential oil (EO) against various drug resistant bacterial pathogens along with studying the molecular docking interactions of the major components of the EO with the key bacterial proteins/enzymes. Gas chromatography-mass spectrometry was used to analyse the chemical composition of the Cupressus funebris EO. The initial antibacterial screening was performed by using disc diffusion and microdilution methods. Scanning electron microscopy was also performed in order to study effects of the EO on bacterial cell morphology. Further, molecular docking studies were performed using Autodock Vina and results were visualised by BIOVIA Discovery Studio. The chemical composition of the EO showed the presence of 15 components with citronellal, terpinene-4-ol, α-phellandrene and 1,8-cineole as the major components of the EO. Results indicated that the EO of Cupressus funebris exhibited dose-dependent as well as time dependent antibacterial effects. The scanning electron microscopy indicated that the Cupressus funebris EO led to membrane rupture and permeabilization of the bacterial cells. Molecular docking studies indicated that the major compounds of the EO (citronellal and terpinene-4ol) showed strong interactions with the active site of the bacterial DNA gyrase enzyme explaining the antibacterial mode of action of the EO. Ciprofloxacin was also used for docking which showed stronger interactions with the target protein than citronellal or terpinene-4-ol. In conclusion, the major findings of the current study were that the EO of Cupressus funebris causes bacterial membrane rupture and permeabilization, shows time-dependent and dose-dependent antibacterial action, along with interacting with crucial bacterial enzyme viz., DNA gyrase as indicated by molecular docking studies.

Keywords: Cupressus funebris; DNA gyrase-B; Essential oil; Molecular docking; Multiple-drug resistance (MDR).

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Figures

Fig. 1
Fig. 1
GC-MS Total Ion Chromatogram (TIC) of the leaf essential oil of Cupressus funebris.
Fig. 2
Fig. 2
The growth curves of the MRSA affected by the essential oil from the leaves of Cupressus funebris. The results were considered significant at p < 0.01.
Fig. 3
Fig. 3
The essential oil of Cupressus funebris induces leakage of important proteins from MRSA. The results were considered significant at *p < 0.01.
Fig. 4
Fig. 4
Scanning electron microscopy (SEM) images of MRSA (methicillin-resistant Staphylococcus aureus); A indicates untreated cells showing normal bacterial morphology, while as B indicates MIC dose of the essential oil. C indicates 2 x MIC dose of the essential oil. The arrows indicate the deformed cellular morphology and ruptured bacterial cells.
Fig. 5
Fig. 5
2D and 3D Structures of (A) Citronellal; PubChem CID_7794, (B) Terpinen-4-ol; PubChem CID_2724161, and (C)Ciprofloxacin; PubChem CID_2764 generated by using ChemBio3D Ultra software.
Fig. 6
Fig. 6
Crystal structure of DNA gyrase B (PDB: 6F86). 3D graphics was generated using Discovery Studio Visualizer 2021.
Fig. 7
Fig. 7
In silico analysis of the binding pattern of Citronellal with DNA-gyrase B protein target; (A) represents cartoon surface representation; (B) (C) and (D) represent Citronellal bound to the active catalytic centre of the protein target; (E) represents the 2D interaction of Citronellal with the important amino acid residues of protein target.
Fig. 8
Fig. 8
In silico analysis of the binding pattern of Terpinen-4-ol with DNA-gyrase B protein target; (A) represents cartoon surface representation; (B) (C) and (D) represent Terpinen-4-ol bound to the active catalytic centre of the protein target; (E) represents the 2D interaction of Terpinen-4-ol with the important amino acid residues of protein target.
Fig. 9
Fig. 9
In silico analysis of the binding pattern of ciprofloxacin with DNA-gyrase B protein target; (A) represents cartoon surface representation; (B) (C) and (D) represent ciprofloxacin bound to the active catalytic centre of the protein target; (E) represents the 2D interaction of ciprofloxacin with the important amino acid residues of protein target.
Fig. 10
Fig. 10
GC-MS generated mass spectra of citronellal (a) and terpinen-4-ol (b).

References

    1. Dadgostar P. Antimicrobial resistance: implications and costs. Infect. Drug Resist. 2019;12:3903–3910. - PMC - PubMed
    1. de Kraker M.E., Stewardson A.J., Harbarth S. Will 10 million people die a year due to antimicrobial resistance by 2050? PLoS Med. 2016;13(11) - PMC - PubMed
    1. Srivastava J., Chandra H., Nautiyal A.R., Kalra S.J.S. Antimicrobial resistance (AMC) and plant-derived antimicrobials (PDAms) as an alternative drug line to control infections. 3 Biotech. 2014;4(5):451–460. - PMC - PubMed
    1. de Lencastre H., Oliveira D., Tomasz A. Antibiotic resistant Staphylococcus aureus: a paradigm of adaptive power. Curr. Opin. Microbiol. 2007;10:428–435. - PMC - PubMed
    1. Livermore D.M. The need for new antibiotics. Clin. Microbiol. Infect. 2004;10(Suppl 4):1–9. - PubMed

LinkOut - more resources